Q3 EPS Forecast for Quest Diagnostics Lifted by Analyst

Quest Diagnostics Incorporated (NYSE:DGX) – William Blair raised their Q3 2025 EPS estimates for Quest Diagnostics in a report issued on Tuesday, October 22nd. William Blair analyst A. Brackmann now expects that the medical research company will post earnings per share of $2.50 for the quarter, up from their prior estimate of $2.45. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.89 per share. William Blair also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.62 EPS and FY2025 earnings at $9.72 EPS.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The company had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.43 billion. During the same period last year, the company posted $2.22 EPS. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year.

Several other research firms also recently commented on DGX. Mizuho lifted their target price on shares of Quest Diagnostics from $160.00 to $174.00 and gave the stock an “outperform” rating in a research report on Thursday. Citigroup lifted their target price on shares of Quest Diagnostics from $165.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird upgraded shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $157.00 to $182.00 in a research report on Wednesday. Finally, Piper Sandler boosted their price target on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “neutral” rating in a research report on Monday, July 29th. Nine investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Quest Diagnostics presently has a consensus rating of “Hold” and an average price target of $163.33.

Quest Diagnostics Stock Down 0.2 %

NYSE:DGX opened at $157.12 on Thursday. The firm’s 50 day simple moving average is $152.88 and its 200 day simple moving average is $144.48. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91. Quest Diagnostics has a one year low of $120.87 and a one year high of $159.94. The company has a market cap of $17.45 billion, a PE ratio of 21.15, a P/E/G ratio of 2.45 and a beta of 0.89.

Institutional Trading of Quest Diagnostics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in Quest Diagnostics by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock valued at $1,853,151,000 after purchasing an additional 345,754 shares in the last quarter. Davis Selected Advisers increased its stake in Quest Diagnostics by 0.4% during the 2nd quarter. Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock valued at $327,257,000 after purchasing an additional 9,665 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Quest Diagnostics by 6.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock valued at $288,758,000 after purchasing an additional 129,395 shares in the last quarter. Nuance Investments LLC increased its stake in Quest Diagnostics by 13.1% during the 1st quarter. Nuance Investments LLC now owns 681,636 shares of the medical research company’s stock valued at $90,733,000 after purchasing an additional 79,152 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Quest Diagnostics by 46.7% during the 1st quarter. BNP Paribas Financial Markets now owns 526,479 shares of the medical research company’s stock valued at $70,080,000 after purchasing an additional 167,623 shares in the last quarter. Institutional investors own 88.06% of the company’s stock.

Insider Activity

In other news, SVP Karthik Kuppusamy sold 1,990 shares of Quest Diagnostics stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the completion of the sale, the senior vice president now owns 11,459 shares in the company, valued at $1,756,206.34. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.79% of the stock is currently owned by company insiders.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 21st. Stockholders of record on Friday, October 4th were paid a $0.75 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $3.00 annualized dividend and a dividend yield of 1.91%. Quest Diagnostics’s dividend payout ratio is currently 40.38%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.